Keywords
How to Cite
Abstract
Breast cancer is the main cause of brain metastases in women. The incidence of brain metastases in breast cancer continues to increase, which is mainly associated with improved systemic therapy, which ensures the control of extracranial metastases and an increase in survival. The management brain metastases of breast cancer remain a challenge, despite the constant improvement of local and systemic therapies. This review of the scientific literature presents the latest data from clinical trials of local and systemic treatment of patients with brain metastatic of breast cancer.
References
American Cancer Society. Cancer Facts & Figures. 2020. https: // doi: www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
Банов С.М., Голанов А.В., Ветлова Е.Р. и др. Результаты радиохирургического лечения пациентов с метастатическим поражением головного мозга // Вопросы онкологии. 2017;63:52–61.
Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology // J Neurooncol. 2005;75:5–14. https: // doi: 10.1007/s11060-004-8093-6
Komorowski AS, Warner E, MacKay HJ et al. Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening? // Clin Breast Cancer. 2020;20: е54-е64. https: // doi: 10.1016/j.clbc.2019.06.007
Sperduto PW, Kased N, Roberge D et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer // J Neurooncol. 2013;112:467–72. https: // doi: 10.1007/s11060-013-1083-9
Subbiah IM, Lei X, Weinberg JS et al. Validation and Development of a Modified Breast Graded Prognostic Assessment as a Tool for Survival in Patients With Breast Cancer and Brain Metastases // JCO. 2015;33:2239–45. https: // doi: 10.1200/JCO.2014.58.8517
Jandial R, Hoshide R, Waters JD, Somlo G. Operative and Therapeutic Advancements in Breast Cancer Metastases to the Brain // Clin Breast Cancer. 2018;18:e455–e467. https: // doi: 10.1016/j.clbc.2017.10.002
Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer // Clin Cancer Res. 2010;16:5664–78. https: // doi: 10.1158/1078-0432.CCR-10-1564
Muacevic A, Wowra B, Siefert A et al. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial // J Neurooncol. 2008;87:299–307. https: // doi: 10.1007/s11060-007-9510-4
Roos DE, Smith JG, Stephens SW. Radiosurgery versus surgery, both with adjuvant whole brain radiotherapy, for solitary brain metastases: a randomised controlled trial // Clin Oncol (R Coll Radiol). 2011;23:646–51. https: // doi: 10.1016/j.clon.2011.04.009
Kondziolka D, Patel A, Lunsford L, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases // International Journal of Radiation Oncology Biology Physics. 1999;45:427–34. https: // doi: 10.1016/S0360-3016(99)00198-4
Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial // The Lancet. 2004;363:1665–72. https: // doi: 10.1016/S0140-6736(04)16250-8
Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial // JAMA. 2006;295:2483–91. https: // doi: 10.1001/jama.295.21.2483
Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial // The Lancet Oncology. 2009;10:1037–44. https: // doi: 10.1016/S1470-2045(09)70263-3
Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study // J Clin Oncol. 2011;29:134–41. https: // doi: 10.1200/JCO.2010.30.1655
Sahgal A, Aoyama H, Kocher M et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis // Int J Radiat Oncol Biol Phys. 2015;91:710–7. https: // doi: 10.1016/j.ijrobp.2014.10.024
Yamamoto M, Serizawa T, Shuto T et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study // Lancet Oncol. 2014;15:387–95. https: // doi: 10.1016/S1470-2045(14)70061-0
Ogura M, Mitsumori M, Okumura S et al. Radiation therapy for brain metastases from breast cancer // Breast Cancer. 2003;10:349–55. https: // doi: 10.1007/BF02967656
Kondziolka D, Kano H, Harrison GL et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article // J Neurosurg. 2011;114:792–800. https: // doi: 10.3171/2010.8. JNS10461
Xu Z, Schlesinger D, Toulmin S, Rich T, Sheehan J. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases // Int J Radiat Oncol Biol Phys. 2012;84:612–8. https: // doi: 10.1016/j.ijrobp.2011.12.054
Gao C, Wang F, Suki D et al. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience // Int J Cancer. 2020;1:1–10. https: // doi: 10.1002/ijc.33243
Soffietti R, Abacioglu U, Baumert B et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) // Neuro-oncology. 2017;19:162–74. https: // doi: 10.1093/neuonc/now241
Дашян Г.А., Семиглазов В.Ф., Криворотько П.В. и др. Роль таргетной терапии в лечении метастатического HER-2-положительного рака молочной железы с поражением головного мозга // Опухоли женской репродуктивной системы. 2016;12:46–51.
Romuald Le Scodan, Ludivine Jouanneau, Christophe Massard et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death // BMC Cancer. 2011;11:395.
Larsen PB, Kümler I, Nielsen DL. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer // Cancer Treat Rev. 2013;39:720–7. https: // doi: 10.1016/j.ctrv.2013.01.006
Park YH, Park MJ, Ji SH et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients // Br J Cancer. 2009;100:894–900. https: // doi: 10.1038/sj.bjc.6604941
Swain SM, Baselga J, Miles D et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA // Ann Oncol. 2014;25:1116–21. https: // doi: 10.1093/annonc/mdu133
Krop IE, Lin NU, Blackwell K et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA // Ann Oncol. 2015;26:113–9. https: // doi: 10.1093/annonc/mdu486
Ricciardi GRR, Russo A, Franchina T et al. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy — a case report and literature review // BMC Cancer. 2018;18:97. https: // doi: 10.1186/s12885-018-3994-5
Jacot W, Pons E, Frenel J-S et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases // Breast Cancer Res Treat. 2016;157:307–18. https: // doi: 10.1007/s10549-016-3828-6
Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study // The Lancet Oncology. 2013;14:64–71. https: // doi: 10.1016/S1470-2045(12)70432-1
Freedman RA, Gelman RS, Anders CK et al. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases // J Clin Oncol. 2019;37:1081–9. https: // doi: 10.1200/JCO.18.01511
Awada A, Colomer R, Inoue K et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial // JAMA Oncol. 2016;2:1557–64. https: // doi: 10.1001/jamaoncol.2016.0237
Awada A, Brufsky A, Saura C et al. Impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer: Findings from the NALA, NEfERT-T, and TBCRC 022 trials. https: // www. pumabiotechnology. Com/d ocs/1 21219_Awada_CNS_SABCS_2019_poster_10_Dec_2019_FINAL.pdf
Colomer R, Cosos D, Del Campo JM et al. Brain metastases from breast cancer may respond to endocrine therapy // Breast Cancer Res Treat. 1988;12:83–6. https: // doi: 10.1007/BF01805745
Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes // J Clin Oncol. 2010;28:3271–7. https: // doi: 10.1200/JCO.2009.25.9820
Raub TJ, Wishart GN, Kulanthaivel P et al. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft // Drug Metab Dispos. 2015;43:1360–71. https: // doi: 10.1124/dmd.114.062745
Anders CK, Le Rhun E, Bachelot TD et al. A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC) // JCO. 2019;37:1017. https: // doi: 10.1200/JCO.2019.37.15_suppl.1017
Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy // Cancer. 1992;69:972–80. https: // doi: 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P
Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma // Cancer. 1999;85:1599–605. https: // doi: 10.1002/(SICI)1097-0142(19990401)85:7<1599: AID-CNCR23>3.0.CO;2-#
Lu Y-S, Chen TW-W, Lin C-H et al. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy // Clin Cancer Res. 2015;21:1851–8. https: // doi: 10.1158/1078-0432.CCR-14-2075
Lin NU, Gelman RS, Younger WJ et al. Phase II trial of carboplatin © and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM) // JCO. 2013;31:513. https: // doi: 10.1200/jco.2013.31.15_suppl.513
Adamo V, Ricciardi GRR, Giuffrida D et al. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study // Ther Adv Med Oncol. 2019;11:1758835919895755. https: // doi: 10.1177/1758835919895755
Колядина И.В., Булавина И.С., Петкау В.В. и др. Потенциал использования эрибулина при метастатическом поражении головного мозга у больных раком молочной железы: научные предпосылки и российский клинический опыт // Современная онкология. 2019;21:17–24. https: // doi: 10.26442/18151434.2019.2.190395
Sirvén MB, Fernández-Ortega A, Stradella A et al. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center // BMC Pharmacol Toxicol. 2019;20:68. https: // doi: 10.1186/s40360-019-0367-x
Cortés J, Rugo HS, Awada A et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial // Breast Cancer Res Treat. 2017;165:329–41. https: // doi: 10.1007/s10549-017-4304-7
Kumthekar P, Tang S-C, Brenner AJ et al. ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases // Clin Cancer Res. 2020. https: // doi: 10.1158/1078-0432.CCR-19-3258
Chamberlain MC, Baik CS, Gadi VK et al. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma // Neuro-oncology. 2017;19: i1-i24. https: // doi: 10.1093/neuonc/now197
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021